EuroBiotech: More Articles of Note


> GammaDelta Therapeutics created a spinout company, Adaptate Biotherapeutics. The spinout will develop antibodies to modulate the activity of gamma delta T cells. Release 

> Amarna Therapeutics raised €10 million ($11 million) to move its SV40-based gene delivery vector platform toward human testing. The Dutch biotech expects to be in the clinic within three years. Statement 

> The city of Amsterdam put out a tender for the development of a medicines business park. The move is intended to build on the relocation of the European Medicines Agency to the city. Release


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Sotio obtained an option to license MaveriX Oncology’s solid tumor drug MVX-5005. The majority owner of Sotio, PPF Group, invested $6.5 million in MaveriX. Statement 

> ISA Pharmaceuticals received a €20 million loan from the European Investment Bank. The loan will fund development of a treatment for HPV16-positive cancers. Release  

> The FDA granted organ drug designation to Minoryx Therapeutics’ leriglitazone in Friedreich’s ataxia. Statement  

Suggested Articles

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.

The Medicines Company, fresh from its turn at the AHA this weekend, has seen its shares jump on growing rumors that Novartis wants to acquire it.